PINDOLOL-10 TAB 10MG TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

PINDOLOL

Disponibbli minn:

PRO DOC LIMITEE

Kodiċi ATC:

C07AA03

INN (Isem Internazzjonali):

PINDOLOL

Dożaġġ:

10MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

PINDOLOL 10MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100/300

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

BETA-ADRENERGIC BLOCKING AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0112362003; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2020-03-09

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
Pr
PINDOLOL – 5
Pr
PINDOLOL – 10
(Pindolol tablets U.S.P.)
Tablets 5 and 10 mg
Antihypertensive/Antianginal Agent
PRO DOC LTÉE
2925, boul. Industriel
Laval, Quebec
H7L 3W9
CONTROL NO: 180570
DATE OF REVISION:
December 19, 2014
NAME OF DRUG
Pr
PINDOLOL – 5
Pr
PINDOLOL – 10
(Pindolol tablets U.S.P.)
Tablets 5, and 10 mg
THERAPEUTIC CLASSIFICATION
Antihypertensive/Antianginal Agent
ACTIONS
PINDOLOL (pindolol) is a beta-adrenergic-receptor blocking agent which
possesses partial
agonist activity (intrinsic sympathomimetic activity-I.S.A). It is
used in the treatment of
hypertension and/or the prophylaxis of angina pectoris.
Hypertension:
The mechanism of the antihypertensive effects of pindolol has not been
established. Among the
factors that may be involved are:
(a) Competitive ability to antagonize catecholamine-induced
tachycardia at the beta-
receptor sites in the heart, thus decreasing cardiac output.
(b) A reduction in total peripheral resistance.
(c) An inhibition of the vasomotor centres.
(d) Inhibition of renin release by the kidneys.
Angina Pectoris:
The mechanism of the antianginal effect of pindolol has not been
established. Pindolol may
reduce the oxygen requirement of the heart at any level of effort by
blocking catecholamine-
induced increases in the heart rate, systolic blood pressure, and the
velocity and extent of
myocardial contraction. However, oxygen requirements may be increased
by such actions as
increases in left ventricular fibre length, end diastolic pressure and
systolic ejection period.
When the net effect is beneficial in anginal patients, it manifests
itself during exercise or stress
by delaying the onset of pain and reducing the incidence and severity
of anginal attacks.
Inman, orally-administered pindolol is rapidly and almost completely
absorbed (≥95%) from the
gastrointestinal tract. The mean absolute bioavailability after oral
administration is about 87-
92%. Plasma levels of 10 to 30 nanogram/mL are associated with its
therapeutic efficacy.
Following sin